Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $282
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $276 to $282.
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $276 to $282.